Reports Q4 (Dec) earnings of $1.53
per share,
$0.12
better thanthe
Capital IQ Consensus Estimate of $1.41; revenues rose 120.0%
year/year to $183.7 mln vs the $185.43 mln consensus. Increases in
total revenues for both the year and the quarter ended December 31,
2012 were driven primarily by inclusion of revenues from the
acquired Azur Pharma and EUSA Pharma businesses and increased net
sales of Xyrem (sodium oxybate) oral solution.
Co issues
guidancefor FY13, sees EPS of $5.70-5.90,
excluding non-recurring items, vs. $5.73 Capital IQ Consensus
Estimate; sees FY13 revs of $805-835 mln vs. $809.65 mln Capital IQ
Consensus Estimate.
JAZZ
Posted by morton13 on 27th of Feb 2013 at 09:50 am
whats up with JAZZ? a nice bullish engulfing candle....
from briefing.com
Posted by morton13 on 27th of Feb 2013 at 09:52 am
Co issues guidancefor FY13, sees EPS of $5.70-5.90, excluding non-recurring items, vs. $5.73 Capital IQ Consensus Estimate; sees FY13 revs of $805-835 mln vs. $809.65 mln Capital IQ Consensus Estimate.
Read more: http://www.briefing.com/GeneralContent/InPlayEQ/Active/TickerSearch/TickerSearchInPlayEq.aspx?SearchTextBox=jazz&SearchType=Ticker&PagePrefix=EQInPlayDualPage&x=21&y=9#ixzz2M6xnDpk1
Under Creative Commons License: Attribution
Follow us: @Briefingcom on Twitter| Briefingcom on Facebook